Anti-inflammatory Peptide Selective COX-2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory drugs, such as NSAIDs and steroids, often have side effects and do not fundamentally cure inflammation, particularly in chronic conditions like chronic rheumatoid arthritis, and there is a need for a substance that can effectively inhibit inflammatory proteins without these drawbacks.
Innovation Solution
A peptide derived from telomerase with an amino acid sequence of SEQ ID NO: 1 or its variants, which has anti-inflammatory properties and can be used in pharmaceutical compositions for treating and preventing Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NSAIDs are used to suppress COX-2 enzyme activity, then anti-inflammatory effect is improved, but COX-1 activity is suppressed causing gastrointestinal disorders
Solution Approach 1:
The patent develops peptides with selective COX-2 inhibitory activity that do not suppress COX-1 enzyme function. This local quality differentiation allows the peptide to target specifically the inflammatory COX-2 pathway while preserving COX-1's protective gastrointestinal functions, thereby achieving anti-inflammatory effects without gastrointestinal side effects
Solution Approach 2:
The patent changes the chemical parameter from small-molecule NSAIDs to peptide-based inhibitors. This parameter change enables selective binding to COX-2 enzyme active site with different structural characteristics, achieving higher selectivity and reduced off-target effects on COX-1 enzyme compared to traditional NSAIDs
2Reliability
If steroids are used to suppress inflammation, then anti-inflammatory effect is improved, but immune system deterioration occurs
Solution Approach 1:
The patent extracts and utilizes only the beneficial anti-inflammatory property from natural substances (peptides from telomerase or other sources) while eliminating the harmful immunosuppressive effects associated with steroids. The peptide selectively inhibits inflammatory pathways without broadly suppressing the immune system
Solution Approach 2:
The patent employs short-lived peptide molecules that exert their anti-inflammatory effect transiently without causing long-term immune system damage. These peptides can be administered as needed to control inflammation without the cumulative immunosuppressive effects of steroid therapy
3Ease of operation
If anti-inflammatory drugs are used to temporarily alleviate inflammation, then symptom relief is improved, but fundamental cure is not achieved
Solution Approach 1:
The patent employs peptides that can prevent the activation of inflammatory pathways before they fully develop. By inhibiting COX-2 enzyme activity early in the inflammatory cascade, the peptide prevents the formation of prostaglandins and other inflammatory mediators, thereby both preventing and treating inflammation at its inception rather than merely alleviating symptoms after they manifest
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.